Lineage Cell Therapeutics (NYSEMKT:LCTX) just reported results for the fourth quarter of 2023.
- Lineage Cell Therapeutics reported earnings per share of -3 cents. This was above the analyst estimate for EPS of -4 cents.
- The company reported revenue of $2.10 million.
- This was 60.31% better than the analyst estimate for revenue of $1.31 million.